Dr. Michael Williams on Lenalidomide Plus Rituximab in First- Line MCL

Video

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses frontline lenalidomide (Revlimid) and rituximab (Rituxan) in mantle cell lymphoma (MCL).

Michael E. Williams, MD, ScM, Byrd S. Leavell Professor of Medicine and Professor of Pathology, University of Virginia Health System, discusses a phase II study that explored frontline lenalidomide (Revlimid) and rituximab (Rituxan) for patients with mantle cell lymphoma (MCL).

In this multicenter, phase II study, led by Jia Ruan, MD, at Weill Cornell Medicine, patients with MCL were treated with lenalidomide and rituximab in both the induction and maintenance setting. At 30 months, the overall response rate for evaluable patients was 92%, and the complete response rate was 64% (95% CI, 46 - 79).

Although it was a small study that only included 38 patients, these findings were impressive, says Williams. The study shows that nonchemotherapy-based approaches can still be very effective, he says. Interestingly, patients experienced the same benifits with the lenalidomide and rituximab combination regardless of whether or not they were classified as having lower or higher-risk MCL, WIlliams notes.

<<<

View more from the 2016 Congress on Hematologic Malignancies

Related Videos
Tycel Phillips, MD
Andre Goy, MD
Patrick I. Borgen, MD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania
Reshma Lillaney Mahtani, DO
Christian Marth, MD, PhD, head, professor, Department of Obstetrics and Gynecology, Innsbruck Medical University
Mansoor Raza Mirza, MD, chief oncologist, Department of Oncology, Rigshospitalet, Copenhagen University Hospital
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology